HBW Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amgen Sensipar Label Prepares For Off-Label Use In Pre-Dialysis Population

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA-crafted labeling for Amgen’s Sensipar anticipates off-label use of the secondary hyperparathyroidism therapy in pre-dialysis patients, review documents for the NDA show.
Advertisement

Related Content

Sensipar Is "Major Breakthrough" For Secondary Hyperparathyroidism – FDA
Sensipar Is "Major Breakthrough" For Secondary Hyperparathyroidism – FDA
Sensipar Is "Major Breakthrough" For Secondary Hyperparathyroidism – FDA
Hectorol pre-dialysis indication

Topics

Advertisement
UsernamePublicRestriction

Register

PS002638

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel